As of November 2024, Alnylam Pharmaceuticals has a market cap of $34.34B. This makes Alnylam Pharmaceuticals the world's 529th valuable company by market cap, according to our data. The market capitalization, also known as a stock market cap is a key financial indication. It represents the combined worth of all the outstanding shares of a publicly traded company multiplied by the current stock price. This figure is often used to see how much a company is worth. This figure is often used to see what is the company net worth.
Year | Market Cap | Change |
---|---|---|
2024 | $18.39B | -23.07% |
2023 | $23.91B | -19.46% |
2022 | $29.68B | 40.14% |
2021 | $21.18B | 30.48% |
2020 | $16.23B | 12.85% |
2019 | $14.39B | 57.96% |
2018 | $9.11B | -42.61% |
2017 | $15.87B | 239.34% |
2016 | $4.68B | -60.23% |
2015 | $11.76B | -2.95% |
2014 | $12.12B | 50.86% |
2013 | $8.03B | 252.33% |
2012 | $2.28B | 123.93% |
2011 | $1.02B | -17.34% |
2010 | $1.23B | -44.04% |
2009 | $2.20B | -28.75% |
2008 | $3.09B | -14.96% |
2007 | $3.63B | 35.89% |
2006 | $2.67B | 60.66% |
2005 | $1.66B | 78.31% |
2004 | $933.05M | - |